Ira Tabas, MD, PHD
Ira Tabas, MD, PhD is the Richard J. Stock Professor of Medicine and Cell Biology at Columbia University. He earned his BS at Tufts University and his MD and PhD at Washington University in St. Louis.
Dr. Tabas conducts research on (1) molecular-cellular mechanisms of atherosclerosis, with an emphasis on endoplasmic reticulum (ER) stress and inflammation in macrophages and dendritic cells; (2) pro-atherogenic roles of insulin resistance and type 2 diabetes; and (3) calcium and ER stress signaling pathways in hepatocytes that contribute to the metabolic disturbances of obesity and diabetes.
The goal of Dr. Tabas’ project with the Harrington Discovery Institute is to translate his discovery of a new pathway controlling metabolism in obesity into a safe and effective treatment for type 2 diabetes (T2D). The hypothesis is that allosteric MAPKAPK2 inhibitors (aMK2-I's) will treat T2D through mechanisms that target glucagon (GCN) signaling and endoplasmic reticulum (ER) stress while avoiding the adverse effects of GCN receptor antagonists.
Dr. Tabas has lectured worldwide and published over 200 original research articles and reviews. These papers have been published in Cell, Nature, Science, Journal of Clinical Investigation, and Proceedings of the National Academy of Sciences. Dr. Tabas also serves on the Board of Reviewing Editors for the journal Science and was elected to both The Society for Clinical Investigation and the Association of American Physicians.